{
    "abstract": "New interleukin (IL)-17A inhibitors seem to demonstrate smaller effects on tuberculosis (TB) reactivation than expected.\nTo evaluate the risk of TB reactivation, to assess serial interferon (IFN)-\u03b3 levels, and to weigh up the risks and benefits of TB chemoprophylaxis in patients with psoriasis treated with IL-17A inhibitors.\nThis dual-centre study included patients with psoriasis who were treated with IL-17A inhibitors. The incidence of active TB, serial IFN-\u03b3 levels tested by IFN-\u03b3 release assays (IGRAs), adverse events (AEs) and effectiveness were evaluated through 1\u2005year in patients with psoriasis treated with IL-17A inhibitors. According to the chemoprophylaxis treatment regimen, patients with latent TB infection (LTBI) were classified into three groups: a complete chemoprophylaxis dose regimen (CCP), an incomplete chemoprophylaxis (ICCP) or no chemoprophylaxis (NCP).\nIn 220 IGRA-negative patients, 17 of 220 (7.3%) became IGRA positive after receiving a mean of 69.1 weeks of IL-17A inhibitor treatment. Only one case of new-onset TB was observed after 52 weeks of ixekizumab therapy. Significant changes in IFN-\u03b3 levels were observed in IGRA-negative patients. Similarly, IFN-\u03b3 levels [listed as the mean (SD)] significantly increased at 1\u2005year compared with baseline among IGRA-positive patients in the NCP [105 (68.7) vs. 236 (80.8) pg mL-1, P < 0.01] and ICCP [75.3 (48.3) vs. 608 (249) pg mL-1, P < 0.001] groups, whereas the changes were not significant [125 (26.6) vs. 131 (21.7) pg mL-1, P = 0.70] in the CCP group.\nDuring IL-17A inhibitor therapy, there is a need for increased awareness of annual screening and assessment of individual risk for early detection of TB infection. LTBI treatment is generally well tolerated and is effective in preventing increased IFN-\u03b3 responses in patients with psoriasis treated with IL-17A inhibitors.",
    "authors": [
        {
            "affiliation": "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.\nNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.\nFurong Laboratory, Changsha, Hunan, China.\nNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.\nHunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.\nHunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.\nXiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, Hunan, China.",
            "firstname": "Kun",
            "initials": "K",
            "lastname": "Hu"
        },
        {
            "affiliation": "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.\nNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.\nFurong Laboratory, Changsha, Hunan, China.\nNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.\nHunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.\nHunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.\nXiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, Hunan, China.",
            "firstname": "Yizhang",
            "initials": "Y",
            "lastname": "Liu"
        },
        {
            "affiliation": "Dalian Dermatosis Hospital, Dalian, Liaoning, China.",
            "firstname": "Yang",
            "initials": "Y",
            "lastname": "Sha"
        },
        {
            "affiliation": "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.\nNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.\nFurong Laboratory, Changsha, Hunan, China.\nNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.\nHunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.\nHunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.\nXiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, Hunan, China.",
            "firstname": "Mi",
            "initials": "M",
            "lastname": "Zhang"
        },
        {
            "affiliation": "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.\nNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.\nFurong Laboratory, Changsha, Hunan, China.\nNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.\nHunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.\nHunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.\nXiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, Hunan, China.",
            "firstname": "Lu",
            "initials": "L",
            "lastname": "Jian"
        },
        {
            "affiliation": "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.\nNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.\nFurong Laboratory, Changsha, Hunan, China.\nNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.\nHunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.\nHunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.\nXiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, Hunan, China.",
            "firstname": "Yongfang",
            "initials": "Y",
            "lastname": "Duan"
        },
        {
            "affiliation": "Dalian Dermatosis Hospital, Dalian, Liaoning, China.",
            "firstname": "Chengzhi",
            "initials": "C",
            "lastname": "Lv"
        },
        {
            "affiliation": "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.\nNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.\nFurong Laboratory, Changsha, Hunan, China.\nNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.\nHunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.\nHunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.\nXiangya Clinical Research Center for Cancer Immunotherapy, Central South University, Changsha, Hunan, China.",
            "firstname": "Yehong",
            "initials": "Y",
            "lastname": "Kuang"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site\u2014for further information please contact journals.permissions@oup.com.",
    "doi": "10.1093/ced/llae549",
    "journal": "Clinical and experimental dermatology",
    "keywords": [],
    "methods": null,
    "publication_date": "2025-02-07",
    "pubmed_id": "39918838",
    "results": "In 220 IGRA-negative patients, 17 of 220 (7.3%) became IGRA positive after receiving a mean of 69.1 weeks of IL-17A inhibitor treatment. Only one case of new-onset TB was observed after 52 weeks of ixekizumab therapy. Significant changes in IFN-\u03b3 levels were observed in IGRA-negative patients. Similarly, IFN-\u03b3 levels [listed as the mean (SD)] significantly increased at 1\u2005year compared with baseline among IGRA-positive patients in the NCP [105 (68.7) vs. 236 (80.8) pg mL-1, P < 0.01] and ICCP [75.3 (48.3) vs. 608 (249) pg mL-1, P < 0.001] groups, whereas the changes were not significant [125 (26.6) vs. 131 (21.7) pg mL-1, P = 0.70] in the CCP group.",
    "title": "Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China.",
    "xml": "<Element 'PubmedArticle' at 0x788502622f70>"
}